• Trial of the Week: MENDS2

  • May 21 2024
  • Length: 1 hr and 18 mins
  • Podcast
Trial of the Week: MENDS2 cover art

Trial of the Week: MENDS2

Listen for free

View show details

  • Summary

  • Trial of the Week: MENDS2 Special Guest: John Devlin, PharmD, BCCCP, MCCM, FCCP @devlinpharmd 03:20 – PADIS background and research introduction 35:25 – MENDS2 discussion John Devlin joins to review the May Trial of the Week “Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis” the MENDS2 study, published in NEJM in 2021. We set the scene by discussing how John developed an interest with PADIS research, discussing PK/PD sedative properties and considerations, landmark trials prior to MENDS2, and how much background work is required for a large RCT. Then we dive into the MENDS2 trial itself. Any significant findings? Biggest methodologic differences from MENDS2 and previous studies? Most challenging process of blinding? Any potential safety concerns? How to avoid unblinding study patients (and why that’s so important)? Plus, trial fun facts, seeing your name in a NEJM research article, applying MENDS2 findings into daily practice, and so much more. Reference list: https://pharmacytodose.com/wp-content/uploads/2024/05/mends2-trial-of-the-week-references.pdf PharmacyToDose.Com @PharmacyToDose PharmacyToDose@Gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices
    Show More Show Less
Physical Illness & Disease Hygiene & Healthy Living
Show More Show Less

What listeners say about Trial of the Week: MENDS2

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.in reviews

Amazon Reviews
No Reviews are Available